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ABSTRACT
Background: The glyoxalase-1 gene (GLO1) is a hotspot for copy-number 
variation (CNV) in human genomes. Increased GLO1 copy-number is associated with 
multidrug resistance in tumour chemotherapy, but prevalence of GLO1 CNV in gastro-
entero-pancreatic neuroendocrine tumours (GEP-NET) is unknown.
Methods: GLO1 copy-number variation was measured in 39 patients with GEP-
NET (midgut NET, n = 25; pancreatic NET, n = 14) after curative or debulking surgical 
treatment. Primary tumour tissue, surrounding healthy tissue and, where applicable, 
additional metastatic tumour tissue were analysed, using real time qPCR. Progression 
and survival following surgical treatment were monitored over 4.2 ± 0.5 years.
Results: In the pooled GEP-NET cohort, GLO1 copy-number in healthy tissue 
was 2.0 in all samples but significantly increased in primary tumour tissue in 43% of 
patients with pancreatic NET and in 72% of patients with midgut NET, mainly driven 
by significantly higher GLO1 copy-number in midgut NET. In tissue from additional 
metastases resection (18 midgut NET and one pancreatic NET), GLO1 copy number 
was also increased, compared with healthy tissue; but was not significantly different 
compared with primary tumour tissue. During mean 3 - 5 years follow-up, 8 patients 
died and 16 patients showed radiological progression. In midgut NET, a high GLO1 copy-
number was associated with earlier progression. In NETs with increased GLO1 copy 
number, there was increased Glo1 protein expression compared to non-malignant tissue.
Conclusions: GLO1 copy-number was increased in a large percentage of patients 
with GEP-NET and correlated positively with increased Glo1 protein in tumour tissue. 
Analysis of GLO1 copy-number variation particularly in patients with midgut NET could 
be a novel prognostic marker for tumour progression.
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INTRODUCTION
Glyoxalase 1 (Glo1) is part of the cytosolic 
glyoxalase system present in all human cells. Glo1 
catalyses the glutathione-dependent metabolism of the 
reactive metabolite methylglyoxal (MG) – Figure 1A. 
MG is formed mainly by the low-level spontaneous 
degradation of triosephosphate intermediates of 
anaerobic glycolysis [1]. It is a potent glycating agent 
of protein and DNA, forming mainly the arginine-
derived hydroimidazolone adduct of arginine residues, 
MG-H1, in proteins; and mainly a mixture of isomeric 
imidazopurinones, MGdG, of DNA – Figures 1B and 1C 
[2, 3]. MG-derived adducts of protein lead to protein 
inactivation and dysfunction and adducts of DNA are 
associated with DNA strand breaks and mutagenesis [4]. 
Glo1 suppresses the concentration of MG to low levels 
and thereby protein and DNA adducts are also suppressed 
to low, tolerable levels in protein and DNA – ca. 1 – 5% 
of protein and 1 in 105 nucleotides in DNA [3, 5, 6]. In 
an animal model of hepatocellular carcinogenesis, GLO1 
was found to be a tumour suppressor gene, suggesting that 
MGdG-linked mutations on some occasions lead to cell 
transformation and malignancy [7]. In established tumours 
increased Glo1 expression is a mediator of multidrug 
resistance (MDR) [8], indicating that MG-mediated 
cytotoxicity may contribute to the mechanism of action of 
antitumour agents – possibly by induction of apoptosis and 
anoikis (cell detachment stimulated apoptosis) [9–11]. Cell 
permeable inhibitors of Glo1 are potential anti-tumour 
agents and counter Glo1-overexpression mediated MDR 
[12] but none have yet been developed for clinical use – 
reviewed in [11, 13].
The human GLO1 gene is located in chromosome 6 
at locus 6p21.2 [14]. It consists of 12 kb with five introns 
separating six exons [15]. It is a hotspot for copy number 
variation (CNV) in non-malignancy. In constructing a 
first-generation CNV map of the human genome, Redon 
et al. found a total of 1,447 CNV regions covering 12% of 
the genome. GLO1 was the only gene found in a copied 
region of ca. 122 kb at ca. 2% prevalence [16]. GLO1 
CNV was confirmed in a further human population study 
[17] and also found in other primates and mice [18–20]. 
GLO1 CNV is functional – increasing Glo1 expression by 
3 – 4 fold in all tissues and cells tested [18]. Importantly, 
GLO1 undergoes amplification in human tumours [21]. In 
a survey of 520 human tumours, increased GLO1 copy-
number was found at a mean prevalence of 8%. The 
highest prevalence was in breast cancer (19%), small cell 
lung cancer (16%) and non-small cell lung cancer (11%) 
[21]. The prevalence of GLO1 copy-number increase in 
patients with gastro-entero-pancreatic neuroendocrine 
tumours (GEP-NET) has not been investigated to date.
GEP-NETs develop from neuroendocrine cells of the 
gastrointestinal tract (GI) mucosa and the pancreatic islet 
cells. The prevalence of GEP-NETs is thought to be 35 
per 100,000 of the population [22], with pancreatic NETs 
(pNETs) representing approximately one third of cases. 
The mainstay of clinical treatment is surgical resection 
of the primary tumour and when possible of metastatic 
disease [23]. However, as a considerable number of 
patients with GEP-NETs present with metastatic disease 
not amenable to surgical resection, further medical 
treatment is required. Somatostatin analogues represent 
the first line of treatment for both functioning symptoms 
and systemic tumour control in patients with well 
differentiated GEP-NET [24, 25]. Additional therapeutic 
options include peptide receptor radionuclide therapy and, 
mainly in patients with pancreatic NET, chemotherapy 
with alkylating agents such as Streptozotocin (STZ), 
Figure 1: The glyoxalase metabolic pathway and prevention of glycation of protein and DNA by methylglyoxal. 
(A) Metabolism of MG by the glyoxalase system. (B) Protein modification by methylglyoxal with formation of arginine-derived 
hydroimidazolone, MG-H1. (C) DNA modification by methylglyoxal with formation of deoxyguanosine-derived imidazopurinone MGdG. 
The adduct residue is shown with guanyl base only. This figure is reproduced with permission from [55]. The major MG glycation adducts 
of protein and DNA are shown, accounting for ca. 90% of total adducts formed. Other minor adducts were described elsewhere [41, 56]
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and treatment with molecular targeted agents such as 
mammalian target of rapamycin (mTOR) inhibitors and 
tyrosine kinase inhibitors [13, 26–28]. However, response 
rates widely vary, with generally better response in 
patients with pancreatic as compared with midgut NET; 
and lack of objective response to chemotherapy in up 
to 60-70% of patients even with pNET [16, 21, 27, 29]. 
Various prospective predictive factors of tumour response 
have been proposed for other tumours, but information in 
patients with GEP-NET is limited and based on studies 
with relatively low numbers [30], also related to the 
low prevalence and heterogeneous nature of NET [31]. 
Identified factors include the proliferation index Ki-67%, 
Akt, PTEN and thymidylate synthase for streptozotocin-
based chemotherapy [30, 32]; and pAKT, PTEN, KRAS, 
FGFR4 mutations for treatment with mTOR inhibitors 
[33]. Here, we have analysed GLO1 CNV in a cohort 
of well characterised patients with GEP-NET who 
had received curative or debulking surgical treatment. 
Information about progression and survival was available 
for a mean 4.2 ± 0.5 years period.
RESULTS
Patient characteristics
Characteristics of included patients with suitable 
histological samples following surgical treatment are 
shown in Table 1. Data are presented separately for 
patients with pancreatic NET (n = 14) and midgut NET 
(n = 25).
GLO1 copy number in neuroendocrine tumour 
tissue of patients with GEP-NET
Previous estimation of GLO1 copy number in 
controls had shown the precision of GLO1 determination 
was (mean ± SD): 2.00 ± 0.13 (n = 21). We therefore 
assumed copy number >0.39 (3 x SD, covering 99.7% of 
the probability) was significantly different from healthy 
control. In pooled analyses (pancreatic and midgut NET 
combined), GLO1 copy number was increased in GEP-
NET tissue, compared with surrounding healthy tissue. 
GLO1 copy number: mean 3.09, 95% CI 2.52 – 3.66. 
Number of GEP-NET cases with change in GLO1 copy 
number, with respect to non-malignant tissue were: 
decreased GLO1 copy number, n = 8; unchanged GLO1 
copy number, n = 6; and increased GLO1 copy number, 
(n = 25); P<0.001, Kruskal-Wallis. Median [lower – 
upper quartile] GLO1 copy number in these groups was: 
unchanged, 2.09 [1.91 – 2.23]; decreased, 1.15 [0.95 – 
1.38], P<0.001; and increased 3.46 [2.90 – 4.28], P<0.001 
(Figure 2A). Therefore, 64% of GEP-NET had increased 
GLO1 copy number. For tumours with metastases, GLO1 
copy number was not changed between primary and 
metastatic tumour: primary tumour, 3.00 [2.25 – 4.04]; 
metastatic tumour 3.55 [2.94 – 6.53], n = 19; Wilcoxon 
Signed Rank test (Figure 2B).
For pancreatic NET, there were 4 tumours with 
unchanged GLO1 copy number, 4 tumours had decreased 
GLO1 copy number and 6 had increased GLO1 copy 
number (P<0.001). In these groups, GLO1 copy number 
was: unchanged 2.05 ± 0.28, decreased 1.31 ± 0.23 
(P<0.01), and increased 3.45 ± 0.73 (P<0.01); t-test. 
Therefore, 43% of pancreatic NET had increased GLO1 
copy number (Figure 2C). Metastatic tissue was available 
only from one patient with pancreatic NET, with a low 
GLO1 copy number of 0.82. Two patients with pancreatic 
NET were excluded from survival and progression 
analyses due to early death after surgical intervention; one 
patient had a high GLO1 copy number in primary tissue 
(4.13) and one had a low GLO1 copy number (0.91).
For midgut NET, there were 4 tumours with 
unchanged GLO1 copy number, 3 tumours had decreased 
GLO1 copy number and 18 with increased GLO1 copy 
number (P<0.01). In these groups, GLO1 copy number 
was: unchanged 2.05 ± 0.16, decreased 1.03 ± 0.35 
(P<0.01), and increased 4.18 ± 1.89 (P<0.01); t-test. 
Therefore, 72% of midgut NET had increased GLO1 
copy number (Figure 2D). For tumours with metastases, 
GLO1 copy number was not changed between primary 
and metastatic tumours. GLO1 copy number was: primary 
tumour, 3.16 [2.37 – 4.61], metastatic tumour 3.63 [3.22 
– 7.06], n = 18; Wilcoxon Signed Rank test, P>0.05. One 
patient with midgut NET had low GLO1 copy number of 
1.24 in metastatic tissue (Figure 2E).
Immunohistochemistry of glyoxalase 1 protein
We could access further archived sample tissue for 
immunohistochemistry (IHC) analysis of Glo1 protein 
in tumour and non-tumour tissue in 29 cases; 7 pNET 
and 22 midgut NET. Tumour GLO1 copy number was 
increased, with respect to non-tumour tissue, in 19 of 
these cases. Glo1 Digital-IHC Score was associated 
positively with Glo1 IHC staining intensity Pathology 
Score. For Pathology scores 1 and 2 combined versus 
3, Glo1 Digital-IHC Score (arbitrary units) were 1.61 ± 
0.33 (n = 14) versus 2.08 ± 0.55 (n = 15), respectively; 
P<0.01, t-test. Overall, there was no correlation of GLO1 
copy with Glo1 Digital-IHC intensity in these NET cases. 
However, for cases showing increased Glo1 Digital-IHC 
Score in tumour versus non-tumour tissue, there was a 
positive correlation of change in Glo1 Digital-IHC Score 
with Glo1 copy number: r = 0.62, P = 0.025; Pearson (n 
= 13). This was also found when cases were selected for 
increased Pathology Score: r = 0.63, P = 0.016; Pearson 
(n = 14).
Progression free and overall survival
The mean progression free survival was shorter in 
patients with pancreatic NET, compared with patients 
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with midgut NET (2.2 ± 0.6 versus 4.0 ± 0.7 years; P = 
0.018); whereas overall survival was not significantly 
different between groups (3.7 ± 0.8 versus 4.6 ± 0.7 years; 
P = 0.51). In patients with midgut NET, time without 
progression was longer in patients with normal or low (< 
2.4) versus increased (≥ 2.4) GLO1 copy-number repeats 
[log Rank (Mantel-Cox), Chi square 5.629, P = 0.018] 
(Figure 3). In contrast, in patients with pancreatic NET, 
time without progression was not significantly different 
in patients with normal or low (< 2.4) versus increased (≥ 
2.4) GLO1 copy-number repeats [log Rank (Mantel-Cox), 
Chi square 0.582, p = 0.46].
Table 1: Clinical characteristics of patients with GEP-NET
Characteristic Pancreatic NET Midgut NET
n 14 25
Age (mean years; range) 62.8 (39 – 75) 66.2 (34 – 89)
Sex (females/males) 8/6 13/12
BMI (kg/m2) 25.4 (19.5 – 34.2) 27.1 (18.6 – 45.2)
Tumour morphology   
 Well differentiated 14 (100%) 25 (100%)
 Poorly differentiated 0 (0%) 0 (0%)
Tumour grade   
 Grade 1 8 (57%) 21 (84%)
 Grade 2 5 (36%) 4 (16%)
 Grade 3 1 (7%)  
Functioning status   
 Functioning (n/%) 1 (7%) 17 (68%)
 Non-functioning (n/%) 13 (93%) 8 (32%)
Biomarkers   
 Serum chromogranin A (pmol/L) 83.2 ± 31.2 296 ± 103
 24-h urine 5-HIAA (μmol/collection) n/a 142 ± 59
Tumour stating   
Tumour extent   
 T1 1 (7.1%) 0 (0%)
 T2 3 (21.4%) 5 (20%)
 T3 7 (50.0%) 11 (44%)
 T4 3 (21.4%) 9 (36%)
Lymph node involvement   
 N0 8 (57.1%) 5 (20%)
 N1 6 (42.9%) 20 (80%)
Systemic disease   
 M0 9 (64.3%) 9 (36%)
 M1 5 (35.7%) 16 (64%)
Survival   
 Progression free survival (days) 797 ± 217 1456 ± 246
 Overall survival (days) 1341 ± 292 1626 ± 264
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At the time of analysis, 6 (15%) of the here 
investigated 39 patients with suitable histological samples 
and complete data had died of disease (Figure 3); of those, 
2/25 patients (8%) died related to a midgut NET and 4/14 
patients (29%) died related to a pancreatic NET, during 
a total observation period of up to11 years following 
surgical treatment of the NET.
Correlation analyses
There was no significant correlation of GLO1 copy 
number with Glo1 mRNA in primary GEP-NET tumours 
(r = 0.20, p = 0.31). In patients with midgut NET, GLO1 
copy number in metastatic tumour tissue strongly and 
significantly positively correlated with chromogranin A 
concentrations (r = 0.70; p = 0.016), as measured directly 
before surgical treatment was performed; but a similar 
correlation of GLO1 copy number with chromogranin A in 
primary tumour tissue was absent (r = 0.27; p = 0.35). In 
contrast, in patients with pancreatic NET there was a very 
strong negative correlation of preoperative chromogranin 
A with GLO1 copy number in primary tumour tissue 
(r =  - 0.94, p = 0.005).
In the entire cohort, overall survival correlated 
with tumour stage T (r = 0.33, P = 0.042), but not with 
functioning status, staging according to nodal or systemic 
disease, type of surgery performed, tumour grade, age, 
BMI or sex (all p > 0.11). There was a strong negative 
correlation of serum Chromogranin A concentrations with 
BMI (r = - 0.51; P = 0.022).
Effect of glyoxalase 1 silencing on the growth of 
pancreatic neuroendocrine tumour BON1 cells 
in vitro
To explore if Glo1 expression may be a factor 
influential in the effectiveness of chemotherapy of NETs, 
we studied the effect of Doxorubicin, a drug which has 
been used in combination with others for treatment of 
NETs – although it is not currently a preferred treatment 
option [38]. We used the BON1 cell line as an in vitro 
model and knocked down Glo1 expression by siRNA 
Figure 2: Change in GLO1 copy number in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs). (A) Change 
of GLO1 copy number in GEP-NETs. Data are median (lower – upper quartile); n = 8 (decreased), n = 6 (unchanged) and n = 25 (increased). 
(B) GLO1 copy number in GEP-NETs – comparison of primary and metastatic tumours. Data are median (lower – upper quartile); n = 19. 
(C) Change of GLO1 copy number in pNETs. Data are mean ± SD; n = 4 (decreased), n = 4 (unchanged) and n = 6 (increased). (D) Change 
of GLO1 copy number in midgut NETs. Data are mean ± SD; n = 3 (decreased), n = 4 (unchanged) and n = 18 (increased). (E) GLO1 copy 
number in midgut NETs – comparison of primary and metastatic tumours. Data are median (lower – upper quartile); n = 18.
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silencing. In control conditions, Doxorubicin inhibited the 
Growth of BON1 cells: GC50 = 3.06 ± 0.13 μM and n = 
2.23 ± 0.20. Glo1 silencing potentiated the inhibition of 
BON1 cell growth by Doxorubicin: with Glo1 silencing, 
GC50 = 1.16 ± 0.13 μM and n = 1.61 ± 0.13. Glo1 silencing 
alone also decreased BON1 cell growth by 27 ± 2% (n 
= 3, P<0.001) under the siRNA transfection conditions 
described (Figure 4).
DISCUSSION
We present herein the first report of GLO1 copy 
number variation in GEP-NET and the finding of high 
prevalence of increased GLO1 copy number – particularly 
of midgut NETs. Increased GLO1 copy number appeared 
to be clinically functional through link to increased tumour 
progression in midgut NET.
Increased GLO1 copy number was previously found 
in other human tumours where the highest prevalence 
was in breast cancer, small cell lung cancer and non-
small cell lung cancer [21]. Here, we show that in our 
cohort of patients with well differentiated GEP-NET, the 
frequency of increased GLO1 copy number was markedly 
higher than in other tumours investigated to date, with 
prevalences of 43% in pancreatic NET and 72% in midgut 
NET, respectively. Comparable GLO1 copy number in 
metastatic and primary tumour indicated that increased 
GLO1 copy number, once acquired by the GEP-NET, 
was maintained. Moreover, increased GLO1 copy number 
was associated with a significantly shorter time to tumour 
progression in patients with midgut NET. Increased GLO1 
copy number and related expression has previously been 
considered permissive for tumour growth with high flux 
of glycolysis and hence flux of formation of MG [3] and 
also resistance to cancer chemotherapy [8]. We also found 
decreased GLO1 copy number in 29% of pancreatic NET 
and 12% midgut NET. This may be due to GLO1 allele 
deletion or tumour genetic instability; or DNA damage in 
sample processing, thereby disrupting binding of primers 
for qPCR.
The observation in our study that Glo1 mRNA 
expression did not significantly correlate with GLO1 
copy number was possibly related to sample size and poor 
efficiency of mRNA extraction from available FFPE tissue 
blocks, which is a limitation of this study. Most mRNA 
and other long RNAs are fragmented during formalin 
fixed, paraffin-embedded (FFPE) tissues [39]. However, in 
more than 80% of the respective cases with higher GLO1 
copy number, mRNA expression was increased as well. 
Importantly, in a genome wide copy number variation 
analysis, GLO1 copy number was among only 3 genes 
out of 600 investigated where consistently increased 
gene expression was confirmed in all investigated tissues 
[18], supporting that GLO1 copy number increases are 
functional.
Figure 3: Time without progression in patients with midgut NET. Time without progression was significantly longer in patients 
with normal or low (< 2.4) versus increased (≥ 2.4) GLO1 copy number [log Rank (Mantel-Cox), Chi square 5.629, p = 0.018]. No 
significant difference in time without progression was observed in patients with pancreatic NET [log Rank (Mantel-Cox), Chi square 0.582, 
p = 0.46]. Blue line: GLO1 copy number < 2.4; green line: GLO1 copy number ≥ 2.4.
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Extraction of DNA and protein from FFPE tissue 
sections is more efficient than for RNA and we therefore 
sought evidence of association of GLO1 copy number 
with Glo1 protein in NET tissue by immunohistochemical 
analysis. Although there was no overall correlation of 
Glo1 Digital-IHC Score with Glo1 copy number, in 
patients where Glo1 Digital-IHC Score was higher than 
in related non-tumour tissue, the increase in Glo1 Digital-
IHC Score correlated positively with GLO1 copy number 
where selection was made by either Glo1 Digital-IHC 
Score of the stained tissue section or by expert pathologist 
assessment. The correlation coefficient values, 0.62 – 0.63, 
suggesting that GLO1 copy number accounts for ca. 40% 
of the variation in Glo1 expression. Therefore, where 
there is increase in Glo1 expression in NETs, GLO1 copy 
number increase appears to be an influential factor.
Increased GLO1 copy number is likely a negative 
survival factor in NETs through its mediation of 
overexpression of Glo1. The latter is permissive for growth 
of tumours with high glycolytic rate and related high flux 
of potentially cytotoxic MG [3]. The clinical treatment 
of patients in this study was by surgical resection of the 
primary NET. Residual primary and metastatic tumours 
with the growth advantage of Glo1 overexpression may 
impact negatively and markedly so on survival. The 
mechanism of GLO1 copy number increase in NETs is 
unknown. Our recent studies suggest it may be driven by 
hypoxia-activated histone demethylase KDM4A/JMJD2A. 
Increased histone demethylation is hypothesised to create 
more open chromatin which promotes inappropriate 
recruitment of mini-chromosome maintenance (MCM) 
proteins and DNA polymerases and thereby facilitate 
re-replication of genomic DNA for copy number gain – 
as recently described [11]. KDM4A is highly expressed 
in many tumours where it is also involved in metabolic 
reprogramming for increased tumour anaerobic glycolysis 
[40].
It might be expected that increased Glo1 expression 
in NETs would be associated with decreased levels of 
protein and DNA glycation adducts. This applies, however, 
if there is no proportionate or disproportionate increase in 
flux of MG in NETs – as indicated by metabolic modelling 
of the glyoxalase pathway [27]. Previous experimental 
studies suggest that tumour cell lines with high GLO1 
copy number and Glo1 expression have high glycolytic 
rate, high flux of MG formation and relatively high 
content of DNA glycation adducts [3, 21]. This likely 
reflects an imperfect adaptation of tumour cells with high 
glycolytic activity to suppress increased MG concentration 
and potential cytotoxicity. MG adducts of protein and 
DNA cannot be reliably assessed in FFPE tissue samples 
as the preservation and analyte extraction procedures 
Figure 4: Effect of doxorubicin on the growth of the pancreatic neuroendocrine tumour cell line and effect of silencing 
of glyoxalase 1. Doxorubicin concentration-response curve for BON1 cell growth in vitro. Key: open symbols and dotted line, wild-
type Glo1 expression; filled symbols and solid line, BON1 cells with Glo1 silencing. Data are mean ± SEM, n = 3 for Doxorubicin 
concentrations 0.25, 0.50, 2.5, 5, 10 and 20 μM. Dose-response curve equations given are: wild-type Glo1 expression, BON1 cell growth 
(% of control) = 100 x 3.062.23/(3.062.23 + [Doxorubicin]2.23); and with Glo1 silencing - BON1 cell growth (% of control) = 73 x 1.161.61/
(1.161.61 + [Doxorubicin]1.61).
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compromise the assays [3, 41]. MG protein and DNA 
adducts may be assessed in NETs in future studies when 
suitable frozen tumour samples have been accumulated.
To assess the likely functionally of Glo1 expression 
in chemotherapy of NETs, we studied the effect of 
doxorubicin, a drug that has been used in combination 
with others for the treatment of NETs [42], on the growth 
of pancreatic NET cell line, BON1. Silencing of Glo1 
potentiated the growth inhibitory effect of doxorubicin 
on BON1 cells and, moreover, also decreased BON1 cell 
growth in the absence of drug treatment. This suggests 
that Glo1 expression may be a factor linked to resistance 
of NETs to doxorubicin and likely other anticancer drugs. 
GLO1 may also suppress cytotoxicity of STZ and cause 
MDR in chemotherapy of pancreatic NET. Cell permeable 
Tat-Glo1 protein prevented STZ-induced toxicity to 
pancreatic beta-cells [43]. Glo1 overexpression was linked 
to MDR in cancer chemotherapy of other tumour types 
[8, 12]. Where Glo1 overexpression was found, resistance 
to cytotoxicity could be overcome by siRNA silencing 
of Glo1 or inhibition by cell permeable Glo1 substrate 
analogue inhibitor [12, 21, 44, 45]. Further studies of 
anticancer drugs with low sensitivity to Glo1-mediated 
MDR for chemotherapy of NETs may now be considered. 
The mechanism of Glo1-mediated MDR is likely the 
suppression of MG-induced apoptosis contributing to the 
mechanism of action of anticancer drugs – as recently 
reviewed [11].
A potential role of GLO1 as a predictive factor for 
both tumour progression and response to treatment could 
be of particular interest, considering that GLO1 is the most 
frequently amplified gene in numerous human cancer cell 
lines [21], with additional GLO1 copies typically being 
functional [21, 27, 29].
We also found that in patients with midgut NET, a 
low GLO1 copy number was associated with increased 
time to tumour progression, thereby possibly representing 
an independent prognostic factor. A similar effect in 
patients with pancreatic NET was absent. These results 
further support the view that pancreatic NET have distinct 
characteristics as compared with midgut NET, with known 
differences in both treatment response and overall survival 
between these types of neuroendocrine malignancies [42, 
46–48].
Incidence of NET has 4 – 5 fold increased in 
Westernized countries from 1973 – 2007, with incidence 
influenced by age, gender, ethnicity and geographic 
location [49]. A family history of cancer was a significant 
risk factor for all NETs. In a USA-based study, a long-term 
history of diabetes mellitus was a risk factor for midgut 
NETs (adjusted odds ratio [AOR] = 5.6), particularly in 
women (AOR = 8.4). Diabetes increased this risk 6-fold 
in women to AOR = 52.2 [50]. There has recently been 
intense interest in the increased cancer risk in patients with 
diabetes. The increase in relative risks associated with 
diabetes are greatest (≥ 2-fold) for cancers of the liver, 
pancreas and endometrium [51]. Midgut NET in women 
appear to also be in this grouping. In the pre-malignant 
state, Glo1 is a tumour suppressor protein [7], which is 
likely mediated through suppression of MG modifications 
of DNA and associated mutagenesis. Diabetes is associated 
with tissue-specific down regulation of Glo1 and increased 
MG [52], which may increase risk of NET tumourigenesis. 
Hyperinsulinemia in type 2 diabetes is also associated with 
an increase of both estrogen and testosterone in women 
but not in men – which stimulates cell proliferation and 
decreases apoptosis [53]. Once malignant transformation 
is established in NETs, the increased Glo1 activity of 
NETs may provide a growth advantage that underlies the 
association of increased GLO1 copy number with poor 
survival.
Further investigations of the clinical impact of 
GLO1 copy number in patients with GEP-NET will 
require multicentre studies with relevant numbers of 
patients who ideally had surgical on repeated occasions; 
and patients with surgical samples from tumour resection 
and subsequent treatment with STZ-based chemotherapy, 
mTOR inhibitors or tyrosine kinase inhibitors in case of a 
future relapse or progression. Neoadjuvant chemotherapy 
for patients with advanced pancreatic NET aiming at 
tumour downsizing before surgical resection has been 
recently proposed as well [54] and may provide further 
opportunities for future research. However, even if a 
relevant number of cases could be achievable in a large 
international multi-centre setting, results of GLO1 CNV 
may be influenced by not rarely observed changes in 
tumour biology of GEP-NET in the chronic setting, and 
by influences of the treatment with cytotoxic agents per se, 
i.e. by increasing cellular MG concentrations and related 
cytotoxicity as part of their mechanism of action [12, 21, 
26].
In further studies it will be important to confirm and 
corroborate the findings of increased GLO1 copy number 
in patients with GEP-NET with a related paralogue ratio 
test and also, in selected samples, examine whether the 
genetic domain increased in copy number is similar to 
that found in other tumours, using high intensity genome-
wide DNA microarray analyses [21, 29]. With increased 
patient numbers and long term (> 10 years) follow-up, 
the association of increased GLO1 copy number and 
expression with rapid progression may be evaluated in 
a case-control study. The current study suggests that 
overexpression of Glo1 through increased GLO1 gene 
copy number in patients with GEP-NET may facilitate 
rapid progression and resistance to therapy – assuming 
a role as it does in other tumour types of mediator of 
MDR.
In conclusion, increased GLO1 copy number was 
a very common molecular pathological event in patients 
with GEP-NET. Measuring GLO1 copy number may 
provide a novel predictive marker to assess the response 
to treatment in systemic disease.
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MATERIALS AND METHODS
Samples for analyses were identified from the GEP-
NET database in the ARDEN NET Centre, University 
Hospitals Coventry and Warwickshire (UHCW) NHS 
Trust, European Neuroendocrine Tumour Society 
(ENETS) Centre of Excellence. Ethics approval had been 
obtained from the ARDEN Tissue Bank, Application 
for Biomaterials (ATB15-004; July 2015; UHCW ethics 
approval 12/SC/0526). Formalin fixed paraffin embedded 
(FFPE) tissue blocks from surgical resection of primary 
tumours and surrounding healthy tissue were available 
from procedures performed between 2005 and 2015. Only 
samples with both available tumour tissue and healthy 
surrounding tissue were selected for analyses. In mixed 
sections, separate cuts from FFPE tissue blocks were 
provided for the purpose of the analyses. The respective 
area of tumour and healthy tissue was determined by a 
Consultant Histopathologist with extensive experience in 
GEP-NET and clearly labelled for further analysis. A total 
of 290 sections and 348 scrolls was received. Two patients 
with pancreatic NET who died early (< 10 days) after 
Whipple’s procedure were excluded, given the impact on 
progression and survival analyses. All patients had well 
differentiated GEP-NET grade 1 or grade 2 GEP-NET, 
with the exception of one patient with pancreatic NET who 
had a grade 3 (Ki-67 proliferation index 25%) but also 
well differentiated tumour. The baseline characteristics 
of the included patients (pancreatic NET; n = 14; midgut 
NET, n= 25) are given in Table 1.
DNA and RNA extraction from tissue sections
DNA extraction from FFPE sections For DNA 
extraction, 2 pieces of 7 ~ 10 μm section scrolls were cut 
in each block. For tissue sections received in binding on 
slides, the healthy tissue and tumour tissue was manually 
scraped respectively in a 1.5 ml Eppendorf tube containing 
500μl of 100% ethanol. After centrifugation at 17,000g for 
10 min at room temperature, the supernatant was discarded 
and open tubes were left in 37°C for ethanol to evaporate 
to dryness. Samples were then incubated twice at 65°C for 
15 min with 1ml of xylene to dissolve and remove paraffin 
and two washes with 100% ethanol to remove residual 
xylene and left to dry. DNA was extracted with Qiagen 
DNeasy® Blood & Tissue Kit. The quantity and quality of 
DNA extraction samples were evaluated with NanoDrop 
1000 and stored the DNA at –20°C until further use.
RNA extraction from FFPE sections For each 
FFPE block, 3 pieces of 7~10 μm section were cut with 
a microtome and stored in the DNase and RNase free 
tubes at 4°C until extraction of total RNA. Total RNA 
was extracted with PureLink FFPE RNA Isolation 
Kit (Invitrogen) and performed according to the 
manufacturer’s instructions. Briefly, sectioned FFPE 
tissue deparaffinised with melting buffer and incubated 
at 72°C for 10 min to melt paraffin. Sections were then 
digested with proteinase K at 60°C for 4 h and centrifuged 
(17,000 g, 10 min, room temperature) to sediment no-
digested tissue and separate paraffin. The supernatant, 
tissue lysate, was transferred to a new tube and 400 μl 
binding buffer and 800 μl 100% ethanol added. The tissue 
lysate was further processed by selective binding of RNA 
to a silica-based membrane in a microspin column. Total 
RNA isolation and purification were performed with 
thorough washing with buffer and RNA eluted in RNase-
free water. The RNA quality and quantity were determined 
with NanoDrop 1000 and stored the RNA at –80°C until 
further use.
Both DNA and RNA extraction yielded good 
quantity and quality of nucleic acid. For pNET, RNA 
and genome DNA in 17 cases out of 18 cases were 
successfully extracted and in midgut NET, all extractions 
from the FFPE samples were successful.
mRNA analysis with quantitative real-time 
polymerase chain reaction (qRT-PCR)
Reverse transcriptase reaction was performed in 20 
μl total volume with 500 ng total RNA with High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems™) 
and run using an Eppendorf Mastercycler gradient. The 
reaction was incubated at 25°C for 10 min, then 37°C for 
2 h, and then 85°C for 5 min. After 3-fold dilution, reverse 
transcription product cDNA (2 μl) was used for qRT-
PCR to detect target gene expression level with TaqMan 
technique on ABI 7500 real time PCR system in 20 μl of 
reaction volume. The initial reaction was at 95 °C for 10 
min, followed by 40 cycles at 95°C for 15 s and 60°C for 
1 min. The primers and probe for Glo1 and ACTB were 
pre-designed primers probe mixture from Life Technology 
Ltd (Paisley, Scotland). Gene expression level was 
evaluated using 2(-ddCt) with ACTB as a reference gene for 
normalization for relative expression level. Analyses were 
performed in triplicate. Values are presented as the relative 
expression of the target gene in tumor tissue compared to 
healthy tissue.
Real-time quantitative PCR for GLO1 copy 
number estimation
Real-time Quantitative PCR was performed 
using TaqMan® Copy number assays protocol (Applied 
Biosystems). The PCR reaction contained: genomic DNA 
(20 ng), 2x concentrated TaqMan master mix (10 μl), 
20x primer-probe working mixture for target gene GLO1 
and reference gene RNase P (1 μl) in 20 μl total reaction 
volume. The PCR reaction was performed with an ABI 
7500 real time PCR system. The cycle conditions were: 
initial cycle, 95°C for 2 min, with following 40 cycles 
at 95°C for 15 s and 60°C for one min. PCR Reactions 
were performed in quadruplicate for each sample. The 
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copy number for each sample was calculated with 2(-ddCt) 
method and the GLO1 copy number in cancer tissue was 
referenced to healthy tissue assuming GLO1 copy number 
2.00. From analysis of GLO1 copy number in the healthy 
human population, qPCR analysis gave GLO1 copy 
number 2.00 ± 0.13 (n = 21). GLO1 copy number outside 
of the interval mean ± SD, 1.61 – 2.39, was considered 
to be significantly different from the normal control 2.00 
copies.
Tissue immunohistochemistry of glyoxalase 1 
protein
Tissue sections (5 μm) of tumour and healthy tissue 
were cut from formalin-fixed paraffin-embedded (FFPE) 
tumour and healthy tissue block with a microtome. 
Sections were immersed in xylene (3 x 5 min), 
isopropanol (2 x 2 min), 70% (v/v) isopropanol/water (1 
x 2 min), and finally rinsed for 2 mins in water. Antigen 
recovery in the sections was performed with 2100 Antigen 
RetrieverTM antigen-retrieval buffer (Aptum Biologics 
Ltd, Southampton, UK) in 10 mM sodium citrate, 0.05% 
Tween-20, pH 6.0, according to the manufacturer’s 
instructions. After antigen-retrieval procedure, the slides 
were rinsed with distilled water (2 x 5 min). For Glo1 
immunostaining, VECTASTAIN Elite ABC (Rabbit 
IgG) Kit (Vector Laboratories, Peterborough, U.K.) 
was used and following the manufacture’s user manual. 
Briefly, sections pre-treated with BLOXALL Endogenous 
Peroxidase and Alkaline Phosphatase Blocking Solution 
to block endogenous peroxidase activity for 10 min at 
room temperature. After washing with tris-buffered saline 
(250 mM Tris, 27 mM KCl, 1.37 M NaCl, pH 7.4, and 1% 
Triton X-100; TBST), serum blocking solution was added 
to sections and incubated at room temperature for 20 min. 
Excess solution was removed by blotting with filter paper 
and the sections were incubated with 1:3000 diluted rabbit 
anti-human GLO1 antibody [34] at 4°C overnight. Slides 
were then washed with TBST, immersed in biotinylated-
anti-human IgG and incubated at room temperature for 
30 min. The slides were then washed in PBS, immersed 
in peroxidase substrate solution, 3,3'-diaminobenzidine 
(DAB; DAB substrate kit, Abcam, Cambridge) at room 
temperature 7 min, rinsed with water and then with 
phosphate buffered Tween (10 mM sodium phosphate, 
0.15M NaCl, 0.05% Tween™ 20, pH 7.5; PBS-Tween). 
Slides were counter-stained with Meyer’s haematoxylin 
(Sigma) for 60 s, rinsed in water and then PBS-Tween. 
The slides were passed through water, 90% EtOH, 100% 
EtOH and xylene (2 min each) and mounted in DPX 
solution (Sigma).
The stained slides were assessed by an 
experienced pathologist (G.K.) and scored for weak, 
moderate and intense Glo1 immunostaining; scores of 
1, 2 and 3, respectively. We also digitised the histology 
slides using the Mirax MidiTM slide scanner (Carl 
Zeiss MicroImaging GmbH, Jena, Germany). Tissue 
regions on the digital slides were identified using 
an entropy based segmentation approach and visual 
fields containing DAB reactivity above a threshold 
were selected automatically. This was done to ensure 
that the automated scoring was restricted to tissue 
segments containing DAB reactivity only. For antigen 
quantification, we first digitally reconstructed separate 
channels for the Haematoxylin and DAB stains in the 
Optical Density space [35]. Automated quantification of 
antigen intensity then proceeded as follows [36]: a. Stain 
intensity was estimated from the DAB channel; and b. 
Statistics from all selected visual fields in the slide were 
combined to represent an overall measure (score) for 
Glo1 protein – referred to as “Digital-IHC Score” below.
Culture of BON1 pancreatic neuroendocrine 
tumour cell line, sensitivity to doxorubicin and 
Glo1 silencing
The BON1 cell line was kindly supplied by 
Professor Courtney Townsend Jr. (University of Texas 
Medical Branch, Galveston, TX, USA). BON1 cells were 
derived from a metastatic human carcinoid tumour of the 
pancreas and are used as a model of pNET cells. BON1 
cells were cultured in Dulbecco’s Modified Eagle Medium/
Nutrient Mixture F-12 (DMEM/F12) medium containing 
2.5 mM L-glutamine, 1:1 (v/v; Thermo Fisher Scientific), 
supplemented with 5% fetal bovine serum (Sigma) and 
1% penicillin/streptomycin (Sigma, Poole, Dorset, U.K.) 
and incubated in 5% CO2 humidified atmosphere at 37°C.
BON1 cells (4 x 104) were seeded in 48-well plates. 
After culture overnight, cells were transfected with 25 
nM Accell Human GLO1 SMART siRNA pool or an 
Accell non-targeting Control siRNA pool (GE Healthcare 
Dharmacon Inc, Little Chalfont, Buckinghamshire, U.K.) 
with Lipofectamine® RNAiMAX Transfection Reagent 
(Thermo Fisher Scientific, Paisley, U.K.) based on the 
manufacture’s protocol. Glo1 silencing was confirmed 
by assay of Glo1 mRNA which was decreased > 95%. 
After 72 hours of transfection, the cells were incubated 
with and without 0.25 – 20 μM doxorubicin. The stock 
solution of doxorubicin was 10 mM in DMSO such that 
the maximum exposure to DMSO was 0.2%. Cell growth 
was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method [37]. Data 
were fitted by non-linear regression to the doxorubicin 
concentration-response equation, A570,Drug/A570,Control = 100 
x GC50
n/(GC50
n + [Doxorubicin]n), solving for GC50 and 
n where A570,Drug/A570,Control is the absorbance at 570 nM in 
MTT incubated extracts from cell incubations with and 
without the anticancer drug, GC50 is the median growth 
inhibitor concentration and n is the logistic regression 
coefficient.
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Statistical analyses
Data are presented as mean ± SD. Continuous 
variables were tested for parametric distribution using 
the Kolmogorov-Smirnov test. Significance of mean and 
median between different groups was evaluated using 
Student’s t test and Mann-Whitney U test, respectively, 
and significance of difference of medians of variables of 
tumours at primary and metastatic sites of the same donor 
were analysed by Wilcoxon’s Signed Rank test. Kruskal-
Wallis test was used for comparing ordinal or non-
normally distributed variables for more than two groups. 
For nominally scaled variables, Chi-square tests were 
applied. Correlation analyses were perfomed by Pearson 
and Spearman methods for parametric and nonparametric 
data distributions, respectively. Progression free survival 
was measured from the time of surgical treatment to 
progression according to RECIST criteria, death or last 
follow up. Overall survival was measured from the time 
of surgical treatment to death. Kaplan Meier survival 
analyses were performed and differences in survival or 
time to progression were estimated using log rank tests. 
A p value < 0.05 was considered statistically significant. 
Data analyses were performed using IBM SPSS Statistics 
version 22 (Chicago, Illinois, USA).
Abbreviations
GLO1, glyoxalase-1 gene; GEP-NET, gastro-entero-
pancreatic neuroendocrine tumour; MG, methylglyoxal; 
CNV, copy number variation; MDR, multidrug resistance; 
STZ, streptozotocin; mTOR, mammalian target of 
rapamycin; FFPE, formalin fixed, paraffin embedded; 
IHC, immunohistochemistry.
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